Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Expert consensus perspective on SGLT inhibitor use in type 1 diabetes, outlining mechanisms, trial design recommendations, and safety requirements rather than presenting new clinical trial data.
This is a systematic review synthesizing mechanistic knowledge and therapeutic evidence to provide a conceptual framework for understanding microbiota–immune interactions in T2DM and guiding future research and clinical translation strategies.
A narrative review synthesizing observational evidence that raises mechanistic questions about diabetes technology and liver disease, but reports no direct clinical outcomes and explicitly acknowledges evidence remains limited, indirect, and inconsistent.
Bioinformatic discovery study with experimental validation in animal models identifying a shared biomarker, but no clinical diagnostic or therapeutic evidence in human subjects.
The Journal of Clinical Endocrinology & Metabolism
A narrative mini-review synthesizing meta-analytic evidence on diabetes clustering in East Asians, proposing subtype-guided clinical strategies without presenting new primary data or a systematic methodology.
A narrative review synthesizing evidence on a proposed reclassification framework for diabetes; provides conceptual guidance on personalized treatment approaches but does not present original efficacy data or comparative clinical outcomes.
This is a narrative review article presenting mechanistic concepts and existing knowledge about microbiota-diabetes relationships, without reporting new primary data, clinical trials, or systematic evidence synthesis.
A narrative feature article reviewing the current state of evidence for immunometabolic approaches in psychiatry, identifying where signal exists versus where speculation predominates, and recommending pathways for translating emerging science into clinical practice.